Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 185 of 6351
-
Can a two-drug combo outsmart resistant lung cancer?
Disease control Not yet recruitingThis Phase 1 study will evaluate the safety, maximum tolerated dose, recommended Phase 2 dose, and preliminary antitumor activity of JIN-A02 in combination with amivantamab in participants with advanced EGFR-mutant non-small cell lung cancer whose disease has progressed after tre…
Phase 1 • Sponsor: Yonsei University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a new targeted drug boost Chemotherapy's power against pancreatic cancer?
Disease control Not yet recruitingCancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. The pancreas is a gland behind the stomach that produces a digestive fluid that is emptied into the intestines through tube shaped ducts. Pancreatic cancer often starts in these du…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Can a new drug help when standard treatment fails for polycythemia vera?
Disease control Not yet recruitingResearchers are looking for new ways to treat polycythemia vera (PV). People with PV may receive treatment to lower the number of red blood cells in the blood, but the usual treatments may not work for everyone. Researchers want to learn if a trial medicine called bomedemstat, al…
Phase 2/3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a pill target cancers with a specific gene flaw?
Disease control Not yet recruitingThis is an open-label, multicenter, exploratory Phase II study to evaluate the efficacy and safety of TR115, an EZH2 inhibitor, in patients with advanced solid tumors carrying ARID1A gene mutations. Approximately 50 participants will be enrolled into three cohorts: platinum-resis…
Phase 2 • Sponsor: Tarapeutics Science Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a vaccine shield children from severe hand, foot, and mouth disease?
Vaccine Not yet recruitingThe purpose of this study is to evaluate the immunogenicity and safety of an inactivated Enterovirus Type 71 (EV71) vaccine, manufactured by Sinovac, in healthy Vietnamese children aged 6 to 71 months. Hand, Foot, and Mouth Disease (HFMD) is a common infectious disease in childr…
Sponsor: Sinovac Biotech Co., Ltd • Aim: Vaccine
Last updated Sep 03, 2026 00:00 UTC
-
Can a new injection slow kidney damage in IgA nephropathy?
Disease control Not yet recruitingThe purpose of this study is to evaluate the long-term safety, tolerability and efficacy of povetacicept in participants with immunoglobulin A nephropathy (IgAN).
Phase 3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a new drug cut seizure days in juvenile myoclonic epilepsy?
Disease control Not yet recruitingThis study is being conducted to evaluate the safety and efficacy of JZP926 capsule in participants with Juvenile Myoclonic Epilepsy (JME).
Phase 2/3 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can targeted radiation outperform surgery for a tough throat cancer?
Disease control Recruiting nowThere remains no uniform treatment modality for glottic laryngeal carcinoma. Current clinical guidelines broadly recommend surgery or radiotherapy as single-modality treatment for early-stage glottic laryngeal carcinoma. Surgery is the predominant treatment modality for patients …
Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a Self-Inhaled vapor beat oral painkillers in the ER?
Symptom relief Not yet recruitingPain is one of the most frequent patient-reported symptoms in emergency departments (EDs). Pain management could be very challenging, notably for patients that must wait in an ED waiting room. In such context, antalgic drugs that could be used are mainly oral medications with the…
Phase 3 • Sponsor: University Hospital, Tours • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Blood test may spot cervical cancer without a biopsy
Diagnosis Recruiting nowThis study aims to explore whether a simple blood test can be used to help detect and monitor cervical cancer. The investigators are studying tiny fragments and particles found in blood, called cell-free DNA (cfDNA) and extracellular vesicles (EVs), to determine whether these can…
Sponsor: Queensland Centre for Gynaecological Cancer • Aim: Diagnosis
Last updated Sep 04, 2026 00:00 UTC
-
Can an oral drug shrink advanced solid tumors?
Disease control Not yet recruitingThis study aims to evaluate the safety and efficacy of RCZY690 therapy in participants with advanced malignant solid tumors. Participants will receive RCZY690 monotherapy until the end of the study.
Phase 1/2 • Sponsor: Rongchang Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a laser drill through the Heart's hardest blockages?
Disease control Not yet recruitingNEON study is a prospective, multicenter, two-cohorts, single arm study evaluating safety, effectiveness and performance of Angimis Atherectomy System for the treatment of Non-crossable and/or Non-dilatable in Coronary Arteries Disease. The primary endpoint assesses the effective…
Sponsor: Shenzhen Tonglu Technology Co., Ltd • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a new pill ease the strain of pulmonary arterial hypertension?
Disease control Not yet recruitingThis Phase 2 study (EPIMODE) will evaluate the efficacy and safety of CS1 compared with placebo when added to standard-of-care therapy in participants with pulmonary arterial hypertension. Participants completing Treatment Period 1 (Week 36) will be re-randomized to continue or …
Phase 2 • Sponsor: Cereno Scientific AB • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can tailored hepatitis c drugs cure infection in kidney patients?
Disease control Not yet recruitingThe goal of this clinical trial is to evaluate the optimal drug therapy of HCV in CKD Patients different stages with or without compensated cirrhosis. The main questions it aims to answer are: outcome measure 1: Efficacy of the treatment by the assessment of sustained virologica…
Phase 2/3 • Sponsor: Tanta University • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
A lifeline for migrant workers: can peer support and an app ease their burden?
Prevention Not yet recruitingMigration is a complex phenomenon with profound health implications. Every year, more than 350,000 Ethiopian women migrate to the Middle East legally, and many others illegally, seeking domestic work. Economic crisis, rising unemployment, and internal conflict contribute to this …
Sponsor: Addis Ababa University • Aim: Prevention
Last updated Aug 27, 2026 00:00 UTC
-
Can a drug rev up the immune system to fight sepsis?
Disease control Not yet recruitingThis study will test whether adding an immune-stimulating drug, nogapendekin alfa inbakicept (NAI), to standard intensive care treatment is safe and potentially helpful for adults with sepsis or septic shock. All participants will receive usual sepsis care. They will also get NA…
Phase 1/2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a new pill stop migraine pain within two hours?
Symptom relief Not yet recruitingThe purpose of this study is to compare the efficacy and safety of BR005-036C versus placebo in subjects with Acute Migraines
Phase 2/3 • Sponsor: Brise Pharmaceuticals Co., Ltd. • Aim: Symptom relief
Last updated Aug 30, 2026 00:00 UTC
-
Switching stomach drugs after transplant may tame a deadly immune attack
Disease control Recruiting nowThe goal of this clinical trial is to observe whether different gastric protection strategies affect the incidence of acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Proton pump inhibitors (PPIs) are r…
Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a new drug make hormone therapy work better for breast cancer?
Disease control Not yet recruitingThis is a single-center, open-label, randomized phase II clinical trial designed to evaluate the efficacy and safety of neoadjuvant Culmerciclib combined with aromatase inhibitor versus aromatase-inhibitor monotherapy in patients with HR-positive, HER2-negative early-stage breast…
Phase 2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a new pill outsmart Drug-Resistant leukemia?
Disease control Not yet recruitingBackground: Chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) are diseases in which the body makes too many white blood cells that do not work properly. Because white cells play a role in immune function, people with CLL/SLL may be at greater risk of infections…
Phase 2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Sep 10, 2026 02:00 UTC